BioCentury | Nov 5, 2019
Product Development

Senti taps tumor-homing MSCs for lead engineered immunotherapy

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to engineer over 60 types of mesenchymal stem cells secreting...
BioCentury | Sep 27, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection In silico , cell culture and mouse studies identified a PGA3-derived antimicrobial peptide that could help treat bacterial infection. In silico screening of amino acid sequences of human secreted proteins for structural similarity...
BioCentury | Feb 27, 2018
Emerging Company Profile

Synth supergroup

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes...
BioCentury | Apr 21, 2014
Company News

Anika, J&J sales and marketing update

...Anika said its U.S. commercialization partner, the DePuy Synthes Mitek Sports Medicine division of Johnson &...
BioCentury | Jan 27, 2014
Financial News

Synthelis completes venture financing

Synthelis , La Tronche, France Business: Proteomics, Supply/Service Date completed: 1/21/14 Type: Venture financing Raised: €610,000 ($826,916) Investors: Rhone Alpes Creation; Alpes Developpement Durable Investissement; Sud Rhone-Alpes Capital; Viaduc; angel investors WIR Staff...
BioCentury | Jun 3, 2013
Company News

Campus Biotech S.A., Merck KGaA, Ecole Polytechnique Federale de Lausanne (EPFL), University of Geneva (UNIGE) other, pharmaceuticals news

...the consortium behind the Campus Biotech initiative has been finalized. Hansjorg Wyss, the founder of Synthes Inc....
BioCentury | Dec 17, 2012
Company News

Alere management update

...Diagnostic Hired: Namal Nawana as COO, effective Dec. 30, formerly president of Johnson Johnson's DePuy Synthes...
BioCentury | Dec 10, 2012
Company News

Campus Biotech S.A., Merck KGaA other news

...former headquarters of Merck's Merck Serono biotech division in Geneva. Hansjorg Wyss, the founder of Synthes Inc....
...regeneration of cardiovascular, muscular and neuromuscular tissue. Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) acquired Synthes...
BioCentury | Dec 8, 2012
Company News

Billionaires make bid for former Merck Serono headquarters

...Serono biotech division of Merck KGaA (Xetra:MRK) in Geneva, Switzerland. Hansjorg Wyss, the founder of Synthes Inc....
...neuroprosthetics and the regeneration of cardiovascular, muscular and neuromuscular tissue. Johnson & Johnson (NYSE:JNJ) acquired Synthes...
BioCentury | Sep 3, 2012
Company News

Axial Biotech, Transgenomic deal

...and termination of certain of Axial's agreements related to ScoliScore. Under the deal, the DePuy Synthes...
Items per page:
1 - 10 of 20
BioCentury | Nov 5, 2019
Product Development

Senti taps tumor-homing MSCs for lead engineered immunotherapy

While Senti’s first disclosed program, SENTI-101, doesn’t incorporate the sense-and-response circuits its scientific founders are known for, the company did use its synthetic biology toolbox to engineer over 60 types of mesenchymal stem cells secreting...
BioCentury | Sep 27, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection In silico , cell culture and mouse studies identified a PGA3-derived antimicrobial peptide that could help treat bacterial infection. In silico screening of amino acid sequences of human secreted proteins for structural similarity...
BioCentury | Feb 27, 2018
Emerging Company Profile

Synth supergroup

With a $53 million series A announced on Tuesday, Senti Biosciences Inc. is combining synthetic biology platform technologies from more than five institutions to build an immunotherapy pipeline and a partnering engine. The company believes...
BioCentury | Apr 21, 2014
Company News

Anika, J&J sales and marketing update

...Anika said its U.S. commercialization partner, the DePuy Synthes Mitek Sports Medicine division of Johnson &...
BioCentury | Jan 27, 2014
Financial News

Synthelis completes venture financing

Synthelis , La Tronche, France Business: Proteomics, Supply/Service Date completed: 1/21/14 Type: Venture financing Raised: €610,000 ($826,916) Investors: Rhone Alpes Creation; Alpes Developpement Durable Investissement; Sud Rhone-Alpes Capital; Viaduc; angel investors WIR Staff...
BioCentury | Jun 3, 2013
Company News

Campus Biotech S.A., Merck KGaA, Ecole Polytechnique Federale de Lausanne (EPFL), University of Geneva (UNIGE) other, pharmaceuticals news

...the consortium behind the Campus Biotech initiative has been finalized. Hansjorg Wyss, the founder of Synthes Inc....
BioCentury | Dec 17, 2012
Company News

Alere management update

...Diagnostic Hired: Namal Nawana as COO, effective Dec. 30, formerly president of Johnson Johnson's DePuy Synthes...
BioCentury | Dec 10, 2012
Company News

Campus Biotech S.A., Merck KGaA other news

...former headquarters of Merck's Merck Serono biotech division in Geneva. Hansjorg Wyss, the founder of Synthes Inc....
...regeneration of cardiovascular, muscular and neuromuscular tissue. Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.) acquired Synthes...
BioCentury | Dec 8, 2012
Company News

Billionaires make bid for former Merck Serono headquarters

...Serono biotech division of Merck KGaA (Xetra:MRK) in Geneva, Switzerland. Hansjorg Wyss, the founder of Synthes Inc....
...neuroprosthetics and the regeneration of cardiovascular, muscular and neuromuscular tissue. Johnson & Johnson (NYSE:JNJ) acquired Synthes...
BioCentury | Sep 3, 2012
Company News

Axial Biotech, Transgenomic deal

...and termination of certain of Axial's agreements related to ScoliScore. Under the deal, the DePuy Synthes...
Items per page:
1 - 10 of 20